DGAT2 and metabolic dysfunction-associated steatohepatitis: In addition, DGAT2 also has its corresponding antisense drug IONIS-DGAT2RX (ClinicalTrials.gov NCT03334214), which is currently in phase 2 of clinical trials for the treatment of NASH (Loomba et al., 2020).